Key Highlights
- All patient treatments in the NMSC Phase I trial were completed, with preliminary data from 14 patients showing no related adverse events.
- Preliminary results recorded a 79% disease control rate and no dose-limiting toxicities, supporting progression to Phase II.
- Two financing arrangements are expected to cover up to about 85% of current and future clinical development costs.
- Cash reserves were A$512,000 at 30 September 2026, compared with A$592,000 at the prior quarter end.
Invion Limited (ASX:IVX) released its quarterly activity and Cash Flow report on 29 October 2026. The Melbourne-based company reported that its non-melanoma skin cancer trial is moving to Phase II, that it has secured two funding arrangements, and that it started a preclinical collaboration with Percheron Therapeutics.
NMSC Trial Progress
All patient treatments in the Phase I non-melanoma skin cancer trial have been completed. Preliminary data from 14 patient readouts showed no adverse events related to treatment, no dose-limiting toxicities and a 79% disease control rate.
On that basis, the company has progressed the programme toward Phase II.
Funding and Collaboration
Invion entered two complementary financing arrangements expected to cover up to about 85% of current and future clinical development costs, including the NMSC trial and an upcoming anogenital cancer trial.
A preclinical Partnership with Percheron Therapeutics will evaluate Photosoft in combination with an immunotherapy. The company refers to earlier Peter MacCallum data showing around 80% tumour control when Photosoft was paired with another checkpoint inhibitor.
Board and Cash
Paul Field joined as an independent non-executive director, and Dr Colin Hopper was appointed clinical advisor earlier. Cash reserves were A$512,000 at quarter end, against A$592,000 at the prior quarter end, and the company reported a positive net Operating Cash Flow for the quarter.
Sector Context and Risks to Watch
Early Clinical Trials of photodynamic and immune-oncology approaches are small, and early results do not establish efficacy in a larger Phase II population. The financing arrangements depend on their terms and conditions being met.
The main risks are the Phase II design and recruitment, the conditions of the financing and the cash balance relative to the clinical programme. Future updates will show the Phase II start and any further financing.
Final Word
Invion has moved its NMSC trial toward Phase II and arranged funding that covers most of its planned clinical costs, while its cash balance is small. The next reports are expected to show the Phase II start and the progress of the Percheron collaboration.






Please wait processing your request...